Oblenio Bio, a Cambridge-based firm focused on autoimmune disease treatments, raises $62M in Series B funding led by Pfizer Ventures to support clinical development of LBL-051.
Amount Raised
$62 Million
Round Type
Series B
CambridgeBiotechnologyHealth CareTherapeuticsInvestors
Description
Oblenio Bio, a company specializing in treating autoimmune diseases, secured $62M in Series B funding. The round was led by Pfizer Ventures, with participation from Deep Track Capital, GV, and Aditum Bio. The funds will be used for the clinical development of LBL-051, a tri-specific T-cell engager. This treatment aims to offer long-term remission for patients with refractory autoimmune diseases.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Oblenio Bio that raised within 45 days of this round, from Fundz verified event records.
- Opal Therapeutics raised $1.3M (Grant) on August 7, 2026.
- Tarsus Pharmaceuticals raised $125M (Post-IPO Equity) on August 6, 2026.
- Expedition raised $115M (Series B) on August 5, 2026.
- Acasti raised $10M on August 4, 2026.
- GentiBio raised $1.2M (Grant) on August 2, 2026.
- Ratio Therapeutics raised $70M (Series C) on July 31, 2026.
Who to call at Oblenio Bio, and when
A new round usually means Oblenio Bio is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Oblenio Bio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Oblenio Bio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Oblenio Bio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Oblenio Bio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansOblenio Bio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.